Grantham, Mayo, Van Otterloo & Co (GMO)
FOLD

Grantham, Mayo, Van Otterloo & Co (GMO)’s Amicus Therapeutics FOLD Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-941,266
Closed -$13.6M – 682
2026
Q1 		$13.6M Buy
+941,266
New +$13.5M 0.03% 217

Other funds holding FOLD

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s FOLD Position: Q2 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 941,266 shares — an estimated $13.6M sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in FOLD in Q1 2026 and held it in 1 quarter. The position peaked at $13.6M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 941,266 Amicus Therapeutics shares in Q2 2026, an estimated $13.6M.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Amicus Therapeutics in Q1 2026 and held it in 1 quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Amicus Therapeutics position peaked at $13.6M in Q1 2026.
  • 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2026, filed 13 Aug 2026.